At this time, Foundation One testing of the primary tumor revealed a tumor mutational burden of 10 mutations per megabase, PDL1 amplification, and PDL2 amplification, as well as microsatellite stability, PTEN loss of exon 2, AURKA amplification, GNAS amplification, JAK2 amplification, 2NF217 amplification, and TP53 loss of exons 2–9. This evidence concerns the gene AURKA and neoplasm.